Status:
COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD
Lead Sponsor:
University of Freiburg
Conditions:
Graft Versus Host Disease
Eligibility:
All Genders
18+ years
Brief Summary
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
Detailed Description
Corticosteroids are the first-line treatment of a GvHD, however many patients do not respond to corticosteroids. Patients with steroid-refractory a GvHD (SR-a GVHD) have a low 1-year survival rate. In...
Eligibility Criteria
Inclusion
- allo-transplanted
- confirmed diagnosis of a GvHD
- age ≥ 18 years
- peripheral blood samples and biopsies available
- written informed consent
- ability to understand the nature of the study and the study-related procedures and to comply with them
Exclusion
- age \< 18 years
- lack of informed consent
- patients that cannot be classified in one of the 2 groups (steroid-refractory, steroid-responsive)
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04342442
Start Date
January 1 2017
End Date
December 31 2019
Last Update
April 13 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.